Intended for U.S. scientific audiences only.
BMS at #ACR19

ACR 2019

Pursuing precision medicine and investigating biomarker science in immune-mediated diseases for patients with unmet needs


t the 2019 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARP) Annual Meeting (November 8 - 13 in Atlanta), we’re presenting 38 Bristol-Myers Squibb-sponsored abstracts, underscoring our commitment to advancing biomarker science and developing more precise approaches to treating immune-mediated diseases where treatment options are limited or medical unmet needs still exist. The presented data include clinical and real-world biomarker studies that focus on furthering precision medicine in rheumatoid arthritis as well as other conditions, including juvenile idiopathic arthritis.

Latest Educational Resources


Five Things to Know about BMS at #ACR19

Learn more about BMS’ presence at this year’s Annual Meeting.

Bristol-Myers Squibb at ACR 2019

Hear perspectives on ACR from BMS leaders.

Advancing Personalized Medicine Research in RA and Beyond

Advancing Personalized Medicine Research in RA and Beyond

Our Dr. Sean E. Connolly explains our personalized medicine research approach and shares a video on the potential role of biomarkers.

Spotlight: Juvenile Idiopathic Arthritis

Spotlight: Juvenile Idiopathic Arthritis

Get the facts on the most common chronic rheumatic disease affecting children and teens.

Spotlight: Rheumatoid Arthritis

Spotlight: Rheumatoid Arthritis

Learn more about this destructive immune-mediated disease and how it can behave differently in different people.

Web of Discovery

Explore immune system interconnectivity.

Immune-Mediated Disease Research Perspectives

Immune-Mediated Disease Research Perspectives

Hear our leaders and scientists explain our latest research.

Disease State Infographics

Disease State Infographics

Learn about the immune-mediated diseases we’re researching.

Five Things to Know about BMS at #ACR19

Since 1934, the American College of Rheumatology (ACR) has worked to improve the care of patients with rheumatic disease.1 Every year, they host an Annual Meeting alongside the Association of Rheumatology Health Professionals (ARP), which draws 16,000+ physicians, health professionals and industry partners from over 100 countries and serves as the premier scientific meeting in rheumatology.2

This year’s meeting takes place November 8-13 in ACR’s home city of Atlanta, Georgia, and promises to feature cutting-edge research and top-rated educational programming across a wide variety of tracks and topics, including the treatment of diseases like rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).2,3

Here are five things to know about what BMS has in store at #ACR19:

1. Presenting over 30 abstracts in RA

BMS is heading south to Atlanta, Georgia, and presenting 38 abstracts this year. The breadth of research being presented includes clinical and real-world data supporting our focuses on furthering precision medicine in rheumatoid arthritis (RA) and addressing unmet patient needs in other conditions, such as moderate-to-severe juvenile idiopathic arthritis (JIA).

2. Advancing biomarker science

We’re continuing to advance biomarker science in order to develop precision medicine in immune-mediated diseases where treatment options are limited.4,5,6

3. Partnering with leading experts in the field

We’re working with physician thought leaders such as Leslie R. Harrold, M.D., M.P.H., Associate Professor of Medicine at University of Massachusetts Medical School and Chief Scientific Officer at Corrona, LLC, to share information related to our clinical research.

4. Sharing real-world findings

Because RA can affect different patients in different ways,6,7 we’re presenting data that replicates previous clinical research findings in a real-world setting – which may be helpful information for rheumatologists as they consider how their patients may respond differently to targeted therapies.5

5. Exploring de-escalation of therapy in RA

The data we’re presenting underscore the potential to positively impact de-escalation regimens in RA patient populations that have historically faced a poor prognosis.4, 5, 8, 9


1. American College of Rheumatology. About Us. Accessed October 30, 2019.
2. American College of Rheumatology. General Meeting Information. Accessed October 30, 2019.
3. American College of Rheumatology. Program. Accessed October 30, 2019.
4. Emery P, Tanaka Y, Bykerk V, et al. Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients With RA: Results From a Randomized Phase IIIb Study. ACR 2019. Abstract.
5. Harrold L, Bryson J, Lehman T, et al. Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment With Abatacept or a TNF Inhibitor in Biologic-Experienced Patients With RA: Results From a US National Observational Study. ACR 2019. Abstract.
6. American College of Rheumatology. Rheumatoid Arthritis. Accessed October 30, 2019.
7.  Smolen J, Aletaha D, Barton A, et al. Rheumatoid Arthritis. Nat Rev Dis Primer. 2018; 1-23.
8.  Catrina A, Svensson C, Malmstrom V, et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol. 2017;13: 1-8.
9. Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: Rheumatoid factors and anticitrullinated protein antibodies. Q J Med. 2009; 103:139-146.
For more information about #ACR19, follow the conversation on @ScienceAtBMS on Twitter.